TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03614117

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius PS7 during 6 months
Description: 7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius PS7 during 3 months
Description: 7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
Study: NCT00922623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero®
Description: Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
Study: NCT01320475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
Study: NCT01836588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional cervix biopsy
Description: Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional cervix biopsy
Description: Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions.
Study: NCT02102035

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct and reversed dorsal digital island flap
Description: The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
Study: NCT04511481

Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction

Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
Study: NCT01192997

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
Study: NCT04051398

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous nerve electrostimulation (TENS) of acupuncture points
Description: TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous nerve electrostimulation (TENS) of acupuncture points
Description: TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
Study: NCT01428258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GMP Diet/GMP Medical Foods
Description: The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AA Diet/AA Medical Foods
Description: The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
Study: NCT04101071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modular ketogenic feed
Description: Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard feed
Description: Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
Study: NCT01174407

Intervention type: OTHER
Intervention: cd 35, cd21, cd55
Description: Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
Study: NCT04739826

Intervention type: DRUG
Intervention: Flumatinib Mesylate
Description: Flumatinib mesylate tablets 600mg qd

Intervention type: DRUG
Intervention: Flumatinib Mesylate
Description: Flumatinib mesylate tablets 600mg qd

Intervention type: DRUG
Intervention: Nilotinib Pill
Description: Nilotinib Capsules 300mg bid

Intervention type: DRUG
Intervention: Nilotinib Pill
Description: Nilotinib Capsules 300mg bid
Study: NCT01913561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Master Caution Garment
Description: Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG gel electrodes
Description: Standard gel electrodes that are been in use in hospital for ECG monitoring.
Study: NCT04189367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western medicine
Description: Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks
Study: NCT02463916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 8 week structured exercise programme

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 8 week structured exercise programme
Study: NCT02542046

Intervention type: DRUG
Intervention: Barium
Description: Administration of barium oral contrast agent prior to CT scan

Intervention type: DRUG
Intervention: Diatrizoate
Description: Administration of diatrizoate oral contrast agent prior to CT scan

Intervention type: DRUG
Intervention: Iohexol
Description: Administration of iohexol oral contrast agent prior to CT scan
Study: NCT04214223

Intervention type: OTHER
Intervention: Pre-Anesthesic Consultation
Description: Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)

Intervention type: OTHER
Intervention: Pre-Anesthesic Consultation
Description: Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)

Intervention type: OTHER
Intervention: Pre-Anesthesic Numerical Evaluation
Description: Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.

Intervention type: OTHER
Intervention: Pre-Anesthesic Numerical Evaluation
Description: Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
Study: NCT01479101

Intervention type: OTHER
Intervention: MammaPrint 70-gene expression profile

Intervention type: OTHER
Intervention: BluePrint 80 gene expression profile
Study: NCT02343146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type One Training (TOT)
Description: The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
Study: NCT04233008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter length
Description: see arm description
Study: NCT00416624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT02849379

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study: NCT04674891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: baseline physical therapy treatment
Description: Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilization exercises
Description: Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~* Hot pack: 10 min~* TENS: 10 min~* Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~* Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week.
Study: NCT02372877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amicus Red Cell Exchange in SCD patients
Description: Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
Study: NCT01640002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propantheline Bromide
Description: 15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
Study: NCT04463472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0301-COVID19
Description: 1.0 mg of AG0301-COVID19 twice at 2-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0301-COVID19
Description: 2.0 mg of AG0301-COVID19 twice at 2-week intervals
Study: NCT01905098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna Detoxification Protocol
Description: All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sauna Detoxification Protocol
Description: All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation Sessions
Description: All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Sessions
Description: All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
Study: NCT02590796

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.

Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.
Study: NCT02489435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02971423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion
Study: NCT02996331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 hour repositioning
Description: Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
Study: NCT02971423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion
Study: NCT02996331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 hour repositioning
Description: It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.